FDA Lifts Hold on Macrogenics Gynecological Cancer Treatment Trial

Dow Jones

Apr 09

By Katherine Hamilton

Macrogenics said the Food and Drug Administration has lifted its partial clinical hold on the oncology company's trial of a cancer treatment.

The hold has been lifted for a Phase 2 study of lorigerlimab as a treatment for gynecological cancers.

The FDA placed a hold on the study in February due to safety issues. Four patients experienced safety events, including thrombocytopenia, myocarditis, neutropenia and concurrent septic shock.

During the hold, existing study participants were able to continue receiving the study drug, the clinical-stage biopharmaceutical company said Wednesday. New participants will be enrolled under a revised protocol that includes additional risk mitigation.

Chief Executive Eric Risser said Macrogenics plans to resume enrollment and is on track to provide a mid-year clinical update.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

April 08, 2026 17:09 ET (21:09 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2626270429"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2626270429\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2626270429?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-09 05:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2626270429","market":"fut","top_or_hot":-1,"title":"FDA Lifts Hold on Macrogenics Gynecological Cancer Treatment Trial","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Macrogenics said the Food and Drug Administration has lifted its partial clinical hold on the oncology company's trial of a cancer treatment. \n</p>\n<p>\n  The hold has been lifted for a Phase 2 study of lorigerlimab as a treatment for gynecological cancers. \n</p>\n<p>\n  The FDA placed a hold on the study in February due to safety issues. Four patients experienced safety events, including thrombocytopenia, myocarditis, neutropenia and concurrent septic shock. \n</p>\n<p>\n  During the hold, existing study participants were able to continue receiving the study drug, the clinical-stage biopharmaceutical company said Wednesday. New participants will be enrolled under a revised protocol that includes additional risk mitigation. \n</p>\n<p>\n  Chief Executive Eric Risser said Macrogenics plans to resume enrollment and is on track to provide a mid-year clinical update. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 08, 2026 17:09 ET (21:09 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Lifts Hold on Macrogenics Gynecological Cancer Treatment Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Lifts Hold on Macrogenics Gynecological Cancer Treatment Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-09 05:09</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Macrogenics said the Food and Drug Administration has lifted its partial clinical hold on the oncology company's trial of a cancer treatment. \n</p>\n<p>\n  The hold has been lifted for a Phase 2 study of lorigerlimab as a treatment for gynecological cancers. \n</p>\n<p>\n  The FDA placed a hold on the study in February due to safety issues. Four patients experienced safety events, including thrombocytopenia, myocarditis, neutropenia and concurrent septic shock. \n</p>\n<p>\n  During the hold, existing study participants were able to continue receiving the study drug, the clinical-stage biopharmaceutical company said Wednesday. New participants will be enrolled under a revised protocol that includes additional risk mitigation. \n</p>\n<p>\n  Chief Executive Eric Risser said Macrogenics plans to resume enrollment and is on track to provide a mid-year clinical update. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 08, 2026 17:09 ET (21:09 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2626270429","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2626270429","pubTimestamp":1775682540,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Macrogenics said the Food and Drug Administration has lifted its partial clinical hold on the oncology company's trial of a cancer treatment.The hold has been lifted for a Phase 2 study of lorigerlimab as a treatment for gynecological cancers.The FDA placed a hold on the study in February due to safety issues. Four patients experienced safety events, including thrombocytopenia, myocarditis, neutropenia and concurrent septic shock.During the hold, existing study participants were able to continue receiving the study drug, the clinical-stage biopharmaceutical company said Wednesday. New participants will be enrolled under a revised protocol that includes additional risk mitigation.Chief Executive Eric Risser said Macrogenics plans to resume enrollment and is on track to provide a mid-year clinical update.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LABU":"三倍做多标普生物-Direxion","MGNX":"MacroGenics Inc.","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"FDA解除对Macrogenics妇科癌症治疗试验的搁置","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MGNX":1.5,"LABU":1.5},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Macrogenics said the Food and Drug Administration has lifted its partial clinical hold on the oncology company's trial of a cancer treatment. \n\n\n  The hold has been lifted for a Phase 2 study of lorigerlimab as a treatment for gynecological cancers. \n\n\n  The FDA placed a hold on the study in February due to safety issues. Four patients experienced safety events, including thrombocytopenia, myocarditis, neutropenia and concurrent septic shock. \n\n\n  During the hold, existing study participants were able to continue receiving the study drug, the clinical-stage biopharmaceutical company said Wednesday. New participants will be enrolled under a revised protocol that includes additional risk mitigation. \n\n\n  Chief Executive Eric Risser said Macrogenics plans to resume enrollment and is on track to provide a mid-year clinical update. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 08, 2026 17:09 ET (21:09 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}